MedTrace Logo

Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease

NCT00228150 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 564

Last updated 2008-12-23

No results posted yet for this study

Summary

The primary objective is to assess the effect of SR57667B at the dose of 4 mg/d on the progression of Parkinson symptoms in patients with early PD. The primary outcome will be the time to progression of disability warranting initiation of L-dopa or a dopamine agonist. Secondary outcomes will comprise assessments of symptoms, activities of daily living and global clinical status.

Conditions

  • Parkinson Disease

Interventions

DRUG

SR57667B

Sponsors & Collaborators

Principal Investigators

  • Mark GUTMAN, MD · Scientific Advisory Committee

  • Werner POEWE, MD · Scientific Advisory Committee

  • Olivier RASCOL, MD · Scientific Advisory Committee

  • Eduardo TOLOSA, MD · Scientific Advisory Committee

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-31
Primary Completion
2006-04-30
Completion
2006-04-30

Countries

  • Austria
  • Canada
  • Denmark
  • France
  • Germany
  • Morocco
  • Netherlands
  • Portugal
  • South Africa
  • Spain
  • Sweden
  • Tunisia
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00228150 on ClinicalTrials.gov